Stablepharma Secures €2.5m EIC Accelerator Grant, Recognised Among Europe's Top 71 Innovators
19.2.2025 13:14:00 CET | Business Wire | Press release
UK-based biotechnology firm Stablepharma Ltd has been awarded €2.5 million through the prestigious European Innovation Council (EIC) Accelerator program. The grant recognises the company’s cutting-edge fridge-free pharmaceutical technology, which meets EIC’s rigorous criteria for excellence, impact, and risk management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219452036/en/
Stablepharma Secures €2.5m EIC Accelerator Grant, Recognised Among Europe's Top 71 Innovators (Photo: Business Wire)
Stablepharma is among 71 companies from 16 countries across Europe selected for this highly competitive funding round, which saw a record 1,211 proposals submitted in 2024. This year’s EIC Accelerator grant marks the most competitive round in Horizon Europe’s history, underscoring the growing demand for innovative solutions across all sectors.
“This EIC Accelerator grant is a clear recognition of Stablepharma’s continued innovation and commitment to making fridge-free vaccines, therapeutics, and diagnostics a reality,” said Ozgur Tuncer, CEO & Executive Director of Stablepharma. “We are incredibly proud to be one of five UK companies awarded this grant. It serves as a testament to the quality and calibre of the UK’s Life Sciences industry and its ongoing advancements.”
Tuncer’s comments underscore the significance of the €2.5 million award, which acknowledges Stablepharma’s leading role in addressing the challenges associated with cold chain logistics, with its groundbreaking fridge-free technology.
The selected companies will collectively receive up to €161 million in grants. The equity investments will be made through the EIC Fund, the EIC’s dedicated investment arm and Europe’s largest deep-tech investor, which typically attracts additional investors and increases the overall investment to more than three times the EIC's original amount.
Stablepharma’s innovative technology platform, StablevaX™, transforms approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This innovation addresses a critical global challenge: the distribution, storage, and wastage issues associated with temperature-sensitive products reliant on the cold chain.
Dr. Steve Chatfield, Non-Executive Chairman of Stablepharma, commented, “We are delighted to have received this grant, given the quality of applicants across Europe. This is a huge accolade to the Stablepharma team who have worked tirelessly to progress our StablevaX™ technology.”
The grant comes as the company moves forward with accelerated Phase 1 clinical trials for its lead candidate, SPVX02, a fridge-free tetanus and diphtheria vaccine in March 2025. The achievement marks a key milestone for Stablepharma, which is on track to revolutionize the global vaccine landscape with its innovative approach to vaccine storage and distribution.
The trial is expected to be completed by early Q3 2025, with results anticipated by Q4 2025, and was part funded by Innovate UK. Stablepharma’s projects align with their commitment to positively impact global health, reduce wastage and ensure equitable access of vaccines.
About Stablepharma:
Stablepharma’s R&D team has identified up to 60 vaccine candidates that could be suitable for StablevaX™ technology. The company actively collaborates with global vaccine manufacturers, academic institutions and NGOs, to advance their pipeline of thermostable products.
StablevaX™ technology can be manufactured under scalable GMP conditions, enabling scale-up of the manufacturing process to provide millions of doses annually.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219452036/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom